The Ypd1 phosphorelay protein is a central constituent of fungal two-component signal transduction pathways. Inhibition of Ypd1 in Saccharomyces cerevisiae and Cryptococcus neoformans is lethal due to the sustained activation of the ‘p38-related’ Hog1 stress-activated protein kinase (SAPK). As two-component signalling proteins are not found in animals, Ypd1 is considered to be a prime antifungal target. However, a major fungal pathogen of humans, Candida albicans, can survive the concomitant sustained activation of Hog1 that occurs in cells lacking YPD1. Here we show that the sustained activation of Hog1 upon Ypd1 loss is mediated through the Ssk1 response regulator. Moreover, we present evidence that C. albicans survives SAPK activation in the short-term, following Ypd1 loss, by triggering the induction of protein tyrosine phosphatase-encoding genes which prevent the accumulation of lethal levels of phosphorylated Hog1. In addition, our studies reveal an unpredicted, reversible, mechanism that acts to substantially reduce the levels of phosphorylated Hog1 in ypd1Δ cells following long-term sustained SAPK activation. Indeed, over time, ypd1Δ cells become phenotypically indistinguishable from wild-type cells. Importantly, we also find that drug-induced down-regulation of YPD1 expression actually enhances the virulence of C. albicans in two distinct animal infection models. Investigating the underlying causes of this increased virulence, revealed that drug-mediated repression of YPD1 expression promotes hyphal growth both within murine kidneys, and following phagocytosis, thus increasing the efficacy by which C. albicans kills macrophages. Taken together, these findings challenge the targeting of Ypd1 proteins as a general antifungal strategy and reveal novel cellular adaptation mechanisms to sustained SAPK activation. As fungi-attributed human deaths are increasing, there is an urgent need to develop new antifungal treatments. Two-component related proteins, such as the Ypd1 phosphorelay protein, have been heralded as antifungal targets as they are not found in humans and because inactivation of YPD1 in several different fungi causes sustained SAPK activation and cell death. However, we have discovered that inactivation of YPD1 in the major human pathogen, Candida albicans, actually enhances virulence. Furthermore, we reveal that this fungus adapts to the sustained activation of the Hog1 SAPK triggered by Ypd1 loss by mounting distinct mechanisms that actively reduce the level of phosphorylated Hog1. These findings question the validity of Ypd1 proteins as broad-spectrum antifungal targets and provide insights into the cellular adaptation to sustained SAPK activation.